Merck has announced the acquisition of Verona Pharma for 10 billion dollars, strengthening its portfolio of respiratory treatments.
Raluca Ioana Draghici
.webp)
Economy
www.shutterstock.com
Always see our news on Google
Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
10:30
Tánczos Barna: Drought Drastically Reduced Grain Production in Three Counties, While Transport Remains the Main Problem
10:22
Meteorologists warn of an unstable winter, amid the formation of the polar vortex and the Super El Niño phenomenon
10:17
Kim Yo Jong, Kim Jong Un’s sister, rejects calls for North Korea’s denuclearization and defends its nuclear arsenal
10:17
Simion told Nicușor Dan that he is “to blame” for the next government, which will be “a disaster”: “It is impossible to reach any stable majority in Parliament”
10:14
King Charles, unusual reaction to Charles Spencer’s criticisms regarding his response after the death of Princess Diana: “The grief caused by the loss of a sibling can cloud reason, impair judgment, and influence memories”
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
